Targeted Therapy
Approved for: NSCLC
Biomarker: MET
Capmatinib (Tabrecta) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has a certain mutation in the MET gene. It is used in adults whose disease has metastasized.
FDA-Approved Lung Cancer Treatments
Capmatinib (Tabrecta)
I want to give in honor of...
name or relation
Donation Amount
other amount